Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis - PubMed

6 days ago

Cytopenia is a common complication in myelofibrosis patients and can worsen with ruxolitinib treatment.
The study categorized 879 ruxolitinib-treated patients into four groups based on cytopenia evolution: never cytopenic, treatment-emergent cytopenia, persistent cytopenia, and improved anemia.
Baseline cytopenia was associated with significantly reduced median overall survival (3.7 vs. 6.7 years) compared to noncytopenic patients.
Patients who remained noncytopenic had the best median overall survival (8.1 years), while those with persistent cytopenia had the worst (3.7 years).
Treatment-emergent cytopenia showed intermediate outcomes (5.1 years), with isolated thrombocytopenia having the poorest prognosis (4.3 years).
Improved anemia was linked to better survival (5.2 years) compared to persistent anemia (3.5 years).
Symptom response mirrored survival trends, with the best outcomes in noncytopenic and improved anemia groups.
The study highlights the prognostic significance of cytopenia dynamics and supports monitoring for risk stratification and treatment optimization.

Hasty Briefsbeta